Related Experiment Video
Updated: May 28, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Hepatitis C virus-mixed cryoglobulinemia-lymphoma relationship
Adriana Nicolau1, R Tănăsescu, Eugenia Bălănescu
1Internal Medicine, "Colentina" Clinical Hospital, Bucharest, RO. adanicolau@yahoo.com
Insights
Hepatitis C virus (HCV) infection is a systemic disease. Mixed cryoglobulinemia (MC), a common HCV complication, involves B lymphocyte proliferation and may evolve into lymphoma, influenced by various factors.
Area of Science:
- Hepatology
- Immunology
- Oncology
Background:
- Hepatitis C virus (HCV) infection is a significant global public health issue, often presenting as a systemic disease.
- Mixed cryoglobulinemia (MC) is the most frequent extrahepatic manifestation of HCV, though cryoglobulinemic vasculitis (CV) prevalence requires further study.
- MC diagnosis relies on serum cryoglobulins, but levels don't predict disease activity or prognosis.
Purpose of the Study:
- To explore the complex nature of HCV infection as a systemic disease.
- To investigate the pathogenesis of mixed cryoglobulinemia (MC) in HCV patients.
- To understand the factors contributing to the evolution of MC and lymphoma in HCV infection.
Main Methods:
- Review of existing literature on HCV, mixed cryoglobulinemia (MC), and lymphoma.
- Analysis of immunological factors implicated in MC and HCV-related B-cell proliferation.
- Discussion of genetic and environmental influences on disease progression.
Main Results:
- HCV infection exhibits systemic manifestations, with MC being a common extrahepatic complication.
- MC is characterized by B lymphocyte polyclonal activation and antibody synthesis.
- Factors like t(14;18) translocation, BAFF, E2-CD81 interaction, regulatory T cells, and type III IFNs may drive MC and lymphoma development.
Conclusions:
- HCV infection should be viewed as a systemic disease with potential for serious complications like MC and lymphoma.
- MC pathogenesis involves B-cell proliferation, and its evolution to lymphoma is a continuous process.
- Identifying key molecular and cellular players is crucial for understanding and managing MC and lymphoma in HCV patients.
Abstract:
HCV (hepatitis C virus) chronic hepatitis has become one the most expensive diseases for public health systems all over the world in the past 10-20 years, a real epidemic, the second most frequent, after hepatitis B virus infection. Due to the complex manifestations, one may consider HCV infection as a "systemic" disease. Mixed cryoglobulinemia (MC) is the most common extrahepatic manifestation of HCV infection, but cryoglobulinemic vasculitis (CV) is considered to be relatively sparse although prevalence studies are needed. Presence of serum cryoglobulins is essential for MC diagnosis, but serum levels do not correlate with the disease activity or prognosis. MC can be defined as a B lymphocyte proliferation disease being characterized by polyclonal activation and antibody synthesis. Evolution to lymphoma should be considered continuous but also other infectious, environmental or genetic factors could be involved. The t (14.18) translocation and Bcl-2 activation in B lymphocytes, B cell-activating factor (BAFF), E2-CD81 interaction, immunoregulatory T CD4+CD25(high) + lymphocytes and type III IFNs might play an important role in MC and lymphoma evolution in HCV patients.
Related Concept Videos
Hepatitis
Cytomegalovirus Disease
Viral Hepatitis I: Introduction
Cirrhosis II: Pathophysiology

